Indivior Pharmaceuticals, Inc.
INDVHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and. With a market capitalization of $4.33B, it sits in mid-cap territory. It develops medicines to treat substance use disorders.
Market Cap
$4.33B
Beta
1.20
P/E (TTM)
18.77
P/E (Fwd)
9.34
EPS (TTM)
$1.95
EPS (Fwd)
$3.92
ROE
—
ROA
22.7%
Cash
$175.0M
Total Debt
$509.0M
Free CF
$44.3M
52W Change
184.7%
Annual Financials
Cash vs Debt
The company holds $175.0M in cash, though total debt stands at $509.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $44.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on assets of 22.7% further supports the picture of efficient asset utilization. Revenue has grown from $901.0M (2022) to $1.24B (2025), reflecting a 38% increase over the period.
As with any equity investment, INDV carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Indivior Pharmaceuticals, Inc.'s trajectory.